Advances in alzheimer's disease drug development

BMC Medicine

Volumn 13, Issue 1, 2015, Pages

  Rafii, Michael S ^a   Aisen, Paul S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Beta amyloid; Clinical trials

Indexed keywords

CRENEZUMAB; PLACEBO; SOLANEZUMAB; 5,6 DIHYDRO 2 IMINO 3 METHYL 6 [4 [5 (1 PROPYNYL) 3 PYRIDINYL] 2 THIENYL] 4 PYRIMIDINONE; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE INHIBITOR; ENCENICLINE; GANTENERUMAB; NERVE GROWTH FACTOR; PF 4494700; PIOGLITAZONE; SARACATINIB; TAU PROTEIN; VANUTIDE CRIDIFICAR; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; DISEASE MARKER; DRUG APPROVAL; DRUG DEVELOPMENT; EPISODIC MEMORY; HUMAN; MEMORY DISORDER; MINI MENTAL STATE EXAMINATION; NATIONAL HEALTH ORGANIZATION; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SECONDARY PREVENTION; AMYLOID NEUROPATHY; CELL LOSS; CHOLINERGIC NERVE CELL; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; GENE THERAPY; IMMUNOTHERAPY; NEUROFIBRILLARY TANGLE; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN CEREBROSPINAL FLUID LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY; TREATMENT DURATION; DRUG DESIGN; PATHOLOGY;

ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; NEUROPROTECTIVE AGENTS;

EID: 84925361346     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-015-0297-4     Document Type: Review

References (44)

1. Wimo A, Jonsson L, Bond J, Prince M, Winblad B. Alzheimer Disease International. The worldwide economic impact of dementia 2010. Alzheimers Dement. 2013;9:1-11. e3.
2. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-44.
3. Jack Jr CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207-16.
4. Bartus RT. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol. 2000;163:495-529.
5. Bartus RT, Dean 3rd RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217:408-14.
6. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1976;8000:1403.
7. Bartus RT. Evidence for a direct cholinergic involvement in the scopolamine induced amnesia in monkeys: effects of concurrent administration of physostigmine and methylphenidate with scopolamine. Pharmacol Biochem Behav. 1978;9:833-6.
8. Doody RS, Dunn JK, Clark CM, Farlow M, Foster NL, Liao T, et al. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord. 2001;12:295-300.
9. Ness S, Rafii M, Aisen P, Krams M, Silverman W, Manji H. Down's syndrome and Alzheimer's disease: towards secondary prevention. Nat Rev Drug Discov. 2012;11:655-6.
10. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature. 2012;488:96-9.
11. Maccioni RB, Lavados M, Maccioni CB, Mujica C, Bosch R, Farías G, et al. Anomalously phosphorylated tau protein and Abeta fragments in the CSF of Alzheimer's and MCI subjects. Neurobiol Aging. 2006;27:237-44.
12. Okamura N, Harada R, Furumoto S, Arai H, Yanai K, Kudo Y. Tau PET imaging in Alzheimer's disease. Curr Neurol Neurosci Rep. 2014;14:500.
13. Kozauer N, Katz R. Regulatory innovation and drug development for early-stage Alzheimer's disease. N Engl J Med. 2013;368:1169-71.
14. Selkoe DJ. Alzheimer's disease. Cold Spring Harb Perspect Biol. 2011;3. doi:10.1101/cshperspect.a004457.
15. Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci. 2007;8:663-72.
16. Braak H, Zetterberg H, Del Tredici K, Blennow K. Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-β changes occur before increases of tau in cerebrospinal fluid. Acta Neuropathol. 2013;126:631-41.
17. Iqbal K, Alonso AC, Gong CX, Khatoon S, Pei JJ, Wang JZ, et al. Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles. J Neural Transm. 1998;53:169-80.
18. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31:1275-83.
19. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280-92.
20. Jack Jr CR, Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V, et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol. 2012;71:765-75.
21. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173-7.
22. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Alzheimer's Disease Cooperative Study Steering Committee; Solanezumab study group. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370:311-21.
23. Cummings J, Cho W, Ward M, Friesenhahn M, Brunstein F, Honigberg L, et al. A randomized, double-blind, placebo-controlled phase 2 study to evaluate the efficacy and safety of crenezumab in patients with mild to moderate Alzheimer's disease. Alzheimers Demen. 2014;10:P275.
24. Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, et al. Gantenerumab: a novel human anti-beta-amyloid antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. J Alzheimers Dis. 2012;28:49-69.
25. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101-12.
26. Forman M, Tseng J, Palcza J, Leempoels J, Ramael S, Krishna G. The novel BACE inhibitor MK-8931 dramatically lowers CSF beta-amyloid peptides in healthy subjects: results from a rising single dose study (PL02. 004). In: 64th American Academy of Neurology Annual Meeting. New Orleans: Neurology; 2012.
27. Forman MS PJ, Tseng J, Dockendorf M, Canales C, Apter J, Backonja M, et al. The novel BACe inhibitor MK-8931 dramatically lowers CSF Abeta peptide in patients with mild to moderate Alzheimer's disease. In: The 11th International Conference on Alzheimer's and Parkinson's Disease. Florence, Italy. 2013.
28. Ryan JM, Grundman M. Anti-amyloid-beta immunotherapy in Alzheimer's disease: ACC-001 clinical trials are ongoing. J Alzheimer Dis. 2009;8:243.
29. Muhs A, Hickman DT, Pihlgren M, Chuard N, Giriens N, Meerschman C, et al. Liposomal vaccines with conformation-specific amyloid antigens define immune response and efficacy in APP transgenic mice. Proc Natl Acad Sci U S A. 2007;8:9810-5.
30. Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, et al. Safety, tolerability, and antibody response of active beta-amyloid immunotherapy with CAD106 in patients with Alzheimer's disease: randomized, double-blind, placebo-controlled, first-in-human study. Lancet Neurol. 2012;8:597-604.
31. Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol. 2010;6:108-19.
32. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Dominantly Inherited Alzheimer Network Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367:795-804.
33. Sigurdsson EM. Tau-focused immunotherapy for Alzheimer's disease and related tauopathies. Curr Alzheimer Res. 2009;6:446-50.
34. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci. 2007;27:9115-29.
35. Hefti F. Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections. J Neurosci. 1986;6:2155-62.
36. Rafii MS, Baumann TL, Bakay RA, Ostrove JM, Siffert J, Fleisher AS, et al. A phase 1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. Alzheimers Dement. 2014;10:571-81.
37. Schmidt AM, Sahagan B, Nelson RB, Selmer J, Rothlein R, Bell JM. The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer's disease. Curr Opin Investig Drugs. 2009;10:672-80.
38. Galasko D, Bell J, Mancuso JY, Kupiec JW, Sabbagh MN, van Dyck C, et al. Clinical trial of an inhibitor of RAGE-beta-amyloid interactions in Alzheimer disease. Neurology. 2014;82:1536-42.
39. Burstein AH, Grimes I, Galasko DR, Aisen PS, Sabbagh M, Mjalli AM. Effect of TTP488 in patients with mild to moderate Alzheimer's disease. BMC Neurol. 2014;14:12.
40. Prickaerts J, van Goethem NP, Chesworth R, Shapiro G, Boess FG, Methfessel C, et al. EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors. Neuropharmacology. 2012;62:1099-110.
41. Miller BW, Willett KC, Desilets AR. Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease. Ann Pharmacother. 2011;45:1416-24.
42. Shirazi SK, Wood JG. The protein tyrosine kinase, Fyn, in Alzheimer's disease pathology. Neuroreport. 1993;4:435-7.
43. Chin J, Palop JJ, Yu GQ, Kojima N, Masliah E, Mucke L. Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J Neurosci. 2004;24:4692-7.
44. Lee G, Thangavel R, Sharma VM, Litersky JM, Bhaskar K, Fang SM, et al. Phosphorylation of tau by Fyn: implications for Alzheimer's disease. J Neurosci. 2004;24:2304-12.